{"disease":{"id":"ptcl","name":"ptcl"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06963632","title":"A Real-world Study on Golidocitinib-based Therapeutic Regimens for the Treatment of Patients With Peripheral T-cell Lymphoma","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT01994382","title":"Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":260,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT05967949","title":"A Retrospective Clinical Study on the First-line Maintenance Treatment of PTCL With Chidamide.","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT03884205","title":"GDPE/CEOPE Compared With CEOPE for Newly Diagnosed Patients With PTCL","phase":"","overall_status":"UNKNOWN","enrollment_count":120,"lead_sponsor_name":"Shandong Provincial Hospital","has_results":false},{"nct_id":"NCT05011058","title":"An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":102,"lead_sponsor_name":"Viracta Therapeutics, Inc.","has_results":true},{"nct_id":"NCT06909877","title":"Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Haihe Biopharma Co., Ltd.","has_results":false},{"nct_id":"NCT05274997","title":"A Phase II Study of Linperlisib (YY-20394) in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":97,"lead_sponsor_name":"Shanghai YingLi Pharmaceutical Co. Ltd.","has_results":false},{"nct_id":"NCT05934513","title":"A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":95,"lead_sponsor_name":"Genfleet Therapeutics (Shanghai) Inc.","has_results":false},{"nct_id":"NCT04423926","title":"Lenalidomide in Combination With CHOP in Patients With Untreated PTCL","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":91,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT07493330","title":"Genotype-guided Targeted Agents Plus EZH2i for Primary Refractory PTCL","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":86,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT03493451","title":"Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":77,"lead_sponsor_name":"BeiGene","has_results":true},{"nct_id":"NCT05225584","title":"Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":56,"lead_sponsor_name":"Kymera Therapeutics, Inc.","has_results":false},{"nct_id":"NCT07139353","title":"Linperlisib Combined With Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":54,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT06495723","title":"Polyspecific Antibodies in Lymphoproliferative T-cell Disorders","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":54,"lead_sponsor_name":"Xenothera SAS","has_results":false},{"nct_id":"NCT04747236","title":"Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"University of Virginia","has_results":false},{"nct_id":"NCT06485219","title":"A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":50,"lead_sponsor_name":"Chengdu Zenitar Biomedical Technology Co., Ltd","has_results":false},{"nct_id":"NCT02594267","title":"A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"Acrotech Biopharma Inc.","has_results":false},{"nct_id":"NCT06492629","title":"Toripalimab Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-Cell Lymphoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":43,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT03240211","title":"Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":37,"lead_sponsor_name":"University of Virginia","has_results":false},{"nct_id":"NCT06925464","title":"CD7 CAR T-Cell Therapy for r/r T-cell Lymphomas","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"Beijing GoBroad Hospital","has_results":false},{"nct_id":"NCT07535762","title":"Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T-Cell Lymphoma","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":36,"lead_sponsor_name":"Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT07022964","title":"CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"Beijing GoBroad Hospital","has_results":false},{"nct_id":"NCT07279584","title":"Golidocitinib Combined With GemOx in RR PTCL","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":31,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT07372352","title":"Zeprumetostat, Azacitidine Combined With Lipo-MIT in R/R PTCL","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":26,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT03900442","title":"Phase 1 Study of PTX-100 in Patients With Advanced Malignancies With PTCL Expansion Cohort","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"Prescient Therapeutics, Ltd.","has_results":false},{"nct_id":"NCT05822050","title":"An Open, Single Center, Non-randomized, Single Arm Clinical Study of Evaluating the Efficacy of Selinexor in the Maintenance Treatment of PTCL","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"The First Hospital of Jilin University","has_results":false},{"nct_id":"NCT07143929","title":"To Observe the CD7-targeted CAR-T Therapy in the Treatment of r/r PTCL","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":18,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT06941688","title":"Evaluating the Effectiveness of Decitabine With Gemcitabine, Oxaliplatin for Relapsed/Refractory Peripheral T-cell Lymphoma","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":17,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT05105412","title":"Lenalidomide and Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphomas","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":12,"lead_sponsor_name":"National Health Research Institutes, Taiwan","has_results":false},{"nct_id":"NCT02689453","title":"Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":11,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04696705","title":"Allogeneic γδ T Cells Immunotherapy in r/r Non-Hodgkin's Lymphoma (NHL) or Peripheral T Cell Lymphomas (PTCL) Patients","phase":"EARLY_PHASE1","overall_status":"UNKNOWN","enrollment_count":10,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT04362007","title":"A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":8,"lead_sponsor_name":"Otsuka Pharmaceutical Co., Ltd.","has_results":true},{"nct_id":"NCT04021082","title":"CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL)","phase":"PHASE2, PHASE3","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Portola Pharmaceuticals","has_results":false},{"nct_id":"NCT04809233","title":"Expanded Access to Tipifarnib","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Kura Oncology, Inc.","has_results":false}],"total":34},"guidelines":[],"source":"Drug Landscape verified database"}